RT Journal Article
SR Electronic
T1 A combination of variant genotypes at two loci in the APOL1 gene is associated with adverse outcomes in SARS-CoV-2: a UK Biobank study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.02.21265755
DO 10.1101/2021.11.02.21265755
A1 Walt Adamson
A1 Harry Noyes
A1 Georgia Beckett-Hill
A1 Anneli Cooper
A1 Annette MacLeod
YR 2021
UL http://medrxiv.org/content/early/2021/11/02/2021.11.02.21265755.abstract
AB The risk of hospitalisation or death from Covid-19 in the UK is disproportionately higher in black ethnic populations than others for reasons that are not fully understood1. In people of African ancestry, variants of the APOL1 gene (G1 and G2) have been associated with risk of a number of non-communicable diseases, such as chronic kidney disease2,3,4,5 and the infectious disease, African sleeping sickness6. Here we test the hypothesis that adverse Covid-19 outcomes are also associated with these variants.Using data from Black UK Biobank participants, we used Firth’s Bias-Reduced Logistic Regression in R to identify APOL1 genotypes that were associated with either hospitalisation or death. APOL1 G1/G2 compound heterozygotes were associated with hospitalisation (OR = 2.4 95% CI: 1.2-4.5) p = 0.010) and death (OR = 5.4, 95% CI: 1.8-15.4, p = 0.004) compared to individuals not carrying the variants. This support hypotheses proposing APOL1 genotype (specifically G1/G2) is a significant contributory factor in the increased rates of poor Covid-19 outcomes observed in people of African ancestry. This has implications for both at the individual and population level by identifying those at higher risk of severe Covid-19 who would benefit from early vaccination and treatment. This is especially relevant to geographical regions where APOL1 G1/G2 genotypes are common such as West and Central Africa6 and their diaspora.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Wellcome Trust (209511/Z/17/Z) and H3Africa (H3A/18/004).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Access to the UK Biobank data was granted for this work under UK Biobank application number 66821.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis research has been conducted using the UK Biobank Resource under application number 66821. All bona fide researchers can apply to use the UK Biobank resource for health related research that is in the public interest. https://www.ukbiobank.ac.uk